Fasting glucagon-like peptide 1 concentration is associated with lower carbohydrate intake and increases with overeating.


Journal

Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594

Informations de publication

Date de publication:
May 2019
Historique:
received: 09 08 2018
accepted: 14 09 2018
pubmed: 5 10 2018
medline: 21 8 2019
entrez: 5 10 2018
Statut: ppublish

Résumé

Glucagon-like peptide 1 (GLP-1) is an incretin hormone that appears to play a major role in the control of food intake. The aim of this investigation was to evaluate and quantify the association of circulating GLP-1 concentration with ad libitum total calorie and macronutrient intake. One-hundred and fifteen individuals (72 men) aged 35 ± 10 years were admitted for an inpatient study investigating the determinants of energy intake. Ad libitum food intake was assessed during 3 days using a reproducible vending machine paradigm. Fasting plasma GLP-1 concentrations were measured on the morning of the first day and on the morning of the fourth day after ad libitum feeding. Plasma GLP-1 concentrations increased by 14% after 3 days of ad libitum food intake. Individuals overate on average 139 ± 45% of weight-maintaining energy needs. Fasting plasma GLP-1 on day 1 was negatively associated with carbohydrate intake (r = - 0.2, p = 0.03) and with daily energy intake from low fat-high simple sugar (r = - 0.22, p = 0.016). Higher plasma GLP-1 concentrations prior to ad libitum food intake were associated with lower carbohydrate intake and lower simple sugar ingestion, indicating a possible role of the GLP-1 in the reward pathway regulating simple sugar intake. ClinicalTrials.gov identifier: NCT00342732.

Identifiants

pubmed: 30284224
doi: 10.1007/s40618-018-0954-5
pii: 10.1007/s40618-018-0954-5
pmc: PMC6447483
mid: NIHMS1508768
doi:

Substances chimiques

Carbohydrates 0
Glucagon-Like Peptide 1 89750-14-1

Banques de données

ClinicalTrials.gov
['NCT00342732']

Types de publication

Journal Article

Langues

eng

Pagination

557-566

Subventions

Organisme : Intramural NIH HHS
ID : ZIA DK069091-12
Pays : United States
Organisme : National Institutes of Health
ID : Z99 DK999999

Références

Int J Obes Relat Metab Disord. 1999 Mar;23(3):304-11
pubmed: 10193877
Br J Nutr. 2000 Mar;83 Suppl 1:S17-20
pubmed: 10889787
J Clin Endocrinol Metab. 2001 Sep;86(9):4382-9
pubmed: 11549680
Lancet. 2002 Mar 9;359(9309):824-30
pubmed: 11897280
Int J Obes Relat Metab Disord. 2003 Nov;27(11):1359-64
pubmed: 14574347
Brain Res. 2005 May 17;1044(1):127-31
pubmed: 15862798
Annu Rev Nutr. 2007;27:389-414
pubmed: 17444812
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14887-8
pubmed: 17855558
Physiol Rev. 2007 Oct;87(4):1409-39
pubmed: 17928588
Curr Opin Pharmacol. 2007 Dec;7(6):607-12
pubmed: 18037344
Annu Rev Psychol. 2008;59:55-92
pubmed: 18154499
J Neurochem. 2008 Jul;106(1):455-63
pubmed: 18397368
Diabetes. 2008 Aug;57(8):2046-54
pubmed: 18487451
Diabetologia. 2008 Dec;51(12):2263-70
pubmed: 18795252
Endocrinology. 2009 Jun;150(6):2654-9
pubmed: 19264875
J Physiol. 2009 May 15;587(Pt 10):2387-97
pubmed: 19332493
Am J Clin Nutr. 2010 Feb;91(2):343-8
pubmed: 19923376
Am J Clin Nutr. 1991 Jun;53(6):1368-71
pubmed: 2035463
N Engl J Med. 2011 Feb 24;364(8):719-29
pubmed: 21345101
Clin Chim Acta. 2011 Jun 11;412(13-14):1191-4
pubmed: 21414305
Front Neurosci. 2011 Mar 03;5:23
pubmed: 21519398
J Addict Med. 2009 Mar;3(1):8-18
pubmed: 21603099
Int J Obes (Lond). 2012 Jun;36(6):843-54
pubmed: 21844879
Am J Physiol Regul Integr Comp Physiol. 2011 Nov;301(5):R1479-85
pubmed: 21849636
Obesity (Silver Spring). 2012 Feb;20(2):313-7
pubmed: 22134200
Clin Endocrinol (Oxf). 2013 Feb;78(2):217-25
pubmed: 22324306
J Neurosci. 2012 Apr 4;32(14):4812-20
pubmed: 22492036
PLoS One. 2012;7(5):e36225
pubmed: 22629311
Nutr Metab (Lond). 2013 Apr 08;10(1):33
pubmed: 23566334
Eur J Endocrinol. 2013 Sep 12;169(4):421-30
pubmed: 23864340
Metabolism. 2014 Feb;63(2):226-32
pubmed: 24290838
J Diabetes Investig. 2010 Apr 22;1(1-2):56-9
pubmed: 24843409
PLoS One. 2015 Mar 20;10(3):e0119034
pubmed: 25793511
J Clin Endocrinol Metab. 2015 Aug;100(8):3011-20
pubmed: 26086330
Br J Nutr. 2017 Jan;117(1):48-55
pubmed: 28115026
Neurosci Biobehav Rev. 2017 Sep;80:457-475
pubmed: 28669754
Lancet. 1987 Dec 5;2(8571):1300-4
pubmed: 2890903
J Endocrinol Invest. 2018 Apr;41(4):439-445
pubmed: 28975572
Metabolism. 2018 Aug;85:116-125
pubmed: 29596853
Diabetes Care. 1997 Jul;20(7):1183-97
pubmed: 9203460
J Clin Invest. 1998 Feb 1;101(3):515-20
pubmed: 9449682
Physiol Behav. 1998 Mar;63(5):919-28
pubmed: 9618017
J Comp Neurol. 1999 Jan 11;403(2):261-80
pubmed: 9886047

Auteurs

A Basolo (A)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), 4212 N. 16th Street, Phoenix, AZ, 85016, USA. alessio.basolo@nih.gov.

S Heinitz (S)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), 4212 N. 16th Street, Phoenix, AZ, 85016, USA.
Department of Medicine, Division of Endocrinology and Nephrology, University of Leipzig, 1Liebigstr. 18, 04103, Leipzig, Germany.

E J Stinson (EJ)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), 4212 N. 16th Street, Phoenix, AZ, 85016, USA.

B Begaye (B)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), 4212 N. 16th Street, Phoenix, AZ, 85016, USA.

M Hohenadel (M)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), 4212 N. 16th Street, Phoenix, AZ, 85016, USA.

P Piaggi (P)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), 4212 N. 16th Street, Phoenix, AZ, 85016, USA.

J Krakoff (J)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), 4212 N. 16th Street, Phoenix, AZ, 85016, USA.

S B Votruba (SB)

Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), 4212 N. 16th Street, Phoenix, AZ, 85016, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH